BLUE RSI Chart
Last 7 days
1%
Last 30 days
-8.2%
Last 90 days
3.1%
Trailing 12 Months
-76.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 4.0M | 9.4M | 21.7M | 0 |
2022 | 4.7M | 6.1M | 5.1M | 3.6M |
2021 | 189.0M | 127.2M | 65.4M | 3.7M |
2020 | 54.1M | 239.7M | 250.0M | 250.7M |
2019 | 51.1M | 56.5M | 53.9M | 44.7M |
2018 | 44.6M | 35.7M | 39.5M | 54.6M |
2017 | 11.5M | 26.7M | 32.8M | 35.4M |
2016 | 9.2M | 5.8M | 6.1M | 6.2M |
2015 | 25.4M | 24.0M | 19.0M | 14.1M |
2014 | 25.4M | 25.4M | 25.4M | 25.4M |
2013 | 1.4M | 7.6M | 13.9M | 20.2M |
2012 | 0 | 274.7K | 307.3K | 340.0K |
2011 | 0 | 0 | 0 | 242.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 04, 2024 | klima thomas j | sold | -6,985 | 1.5276 | -4,573 | see remarks |
Mar 04, 2024 | obenshain andrew | sold | -9,310 | 1.5276 | -6,095 | president and ceo |
Mar 01, 2024 | colvin richard a | sold | -10,341 | 1.5276 | -6,770 | chief medical officer |
Feb 05, 2024 | klima thomas j | sold | -2,449 | 0.9025 | -2,714 | see remarks |
Feb 05, 2024 | obenshain andrew | sold | -1,695 | 0.9025 | -1,879 | president and ceo |
Feb 05, 2024 | vittiglio joseph | sold | -4,708 | 0.9025 | -5,217 | chief business & legal officer |
Jan 05, 2024 | obenshain andrew | sold | -4,519 | 1.4294 | -3,162 | president and ceo |
Jan 05, 2024 | colvin richard a | sold | -844 | 1.415 | -597 | chief medical officer |
Dec 06, 2023 | krawtschuk christopher | sold | -20,437 | 4.5155 | -4,526 | chief financial officer |
Nov 03, 2023 | obenshain andrew | sold | -2,554 | 3.1659 | -807 | president and ceo |
Which funds bought or sold BLUE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | DIMENSIONAL FUND ADVISORS LP | reduced | -45.00 | -2,024,710 | 2,108,860 | -% |
May 10, 2024 | JPMORGAN CHASE & CO | added | 10.09 | 51,286 | 2,474,340 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 77.21 | 44,494 | 113,610 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | reduced | -3.16 | -7,132 | 62,965 | -% |
May 10, 2024 | AJOVista, LLC | new | - | 24,579 | 24,579 | 0.07% |
May 10, 2024 | Sargent Investment Group, LLC | added | 42.69 | 12,205 | 49,933 | 0.01% |
May 10, 2024 | VANGUARD GROUP INC | added | 19.64 | 1,328,010 | 13,438,000 | -% |
May 10, 2024 | PNC Financial Services Group, Inc. | added | 45.99 | 579 | 2,214 | -% |
May 10, 2024 | CREDIT SUISSE AG/ | sold off | -100 | -97,483 | - | -% |
May 10, 2024 | BlackRock Inc. | added | 68.97 | 7,032,020 | 19,428,600 | -% |
Unveiling Bluebird Bio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bluebird Bio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.2B | 6.8B | -8.07 | 7.03 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.44 | 4.66 | ||||
NVAX | 1.8B | 996.6M | -4.62 | 1.85 | ||||
CRBP | 458.7M | 881.7K | -13.59 | 481.06 | ||||
INO | 294.6M | 4.9M | -2.36 | 60.54 | ||||
IBIO | 15.6M | 2.1M | -0.67 | 7.61 |
Bluebird Bio Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | 79.9% | 12,392,000 | 6,890,000 | 2,381,000 | 63,000 | 70,000 | 1,519,000 | 1,945,000 | 1,606,000 | 1,019,000 | 143,000 | 5,425,500 | 10,708,000 | 19,273,000 | 198,890,000 | 21,863,000 | 9,997,000 | 8,910,000 | 13,296,000 | 12,471,000 | 19,243,000 | 11,528,000 |
Cost Of Revenue | 14.5% | 10,955,000 | 9,564,000 | 3,376,000 | - | - | 1,745,000 | 8,310,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 153.7% | 1,437,000 | -2,674,000 | -995,000 | - | 71,000 | -226,000 | -6,365,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Costs and Expenses | 4.3% | 86,166,000 | 82,623,000 | 83,498,000 | 86,683,000 | 84,852,000 | 107,174,000 | 113,981,000 | 137,273,000 | 155,468,000 | 154,844,000 | 146,988,000 | 139,387,000 | 131,743,000 | 143,650,000 | 144,479,000 | 240,531,000 | 219,326,000 | 215,998,000 | 183,645,000 | 176,204,000 | 161,347,000 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 176,204,000 | 161,347,000 |
S&GA Expenses | 0.9% | 40,703,000 | 40,349,000 | 37,354,000 | 30,706,500 | 33,402,000 | 36,694,000 | 36,106,000 | 51,196,500 | 42,229,000 | 54,984,000 | 63,569,000 | 30,028,000 | 68,046,000 | 68,628,000 | 73,248,000 | 40,684,000 | 66,250,000 | 68,631,000 | 60,279,000 | 53,508,000 | 44,527,000 |
R&D Expenses | 7.5% | 45,463,000 | 42,274,000 | 46,144,000 | 45,899,500 | 53,149,000 | 63,841,000 | 77,875,000 | 79,082,000 | 73,679,000 | 84,645,000 | 82,843,000 | -131,553,000 | 140,431,000 | 156,308,000 | 154,123,000 | -93,473,000 | 151,412,000 | 146,540,000 | 122,640,000 | 119,722,000 | 116,744,000 |
EBITDA Margin | 58.8% | -3.99 | -9.70 | -29.26 | -72.69 | -82.68 | -81.59 | -116 | -148 | -8.40 | -4.66 | -2.43 | -2.16 | - | - | - | - | - | - | - | - | - |
Income Taxes | 100.0% | - | -80,000 | - | 110,000 | 7,000 | - | - | 89,000 | -113,000 | 216,000 | 66,000 | 253,000 | 329,000 | 10,000 | 94,000 | 203,000 | -264,000 | -469,000 | -15,000 | - | - |
Earnings Before Taxes | 1.7% | -71,731,000 | -72,988,000 | 21,240,000 | 32,342,000 | -76,513,000 | -100,138,000 | -122,152,000 | -132,238,000 | -152,947,000 | -155,757,000 | -121,438,000 | -141,982,000 | -194,416,000 | -21,455,000 | -202,517,000 | 11,442,000 | -206,297,000 | -196,251,000 | -164,461,000 | -148,836,000 | -145,480,000 |
EBT Margin | 58.9% | -4.19 | -10.20 | -30.52 | -74.08 | -83.86 | -83.34 | -119 | -153 | -8.74 | -4.82 | -2.54 | -2.23 | - | - | - | - | - | - | - | - | - |
Net Income | 1.6% | -71,731,000 | -72,908,000 | 21,240,000 | 32,232,000 | -76,520,000 | -100,138,000 | -122,152,000 | -155,052,000 | -216,816,000 | -241,702,000 | -205,808,000 | -199,874,000 | -194,745,000 | -21,465,000 | -202,611,000 | -223,347,000 | -206,033,000 | -195,782,000 | -164,446,000 | -149,023,000 | -145,480,000 |
Net Income Margin | 58.9% | -4.20 | -10.20 | -30.54 | -74.11 | -88.30 | -97.58 | -156 | -223 | -13.21 | -6.62 | -3.29 | -2.47 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 13.0% | -63,884,000 | -73,467,000 | -86,870,000 | -56,381,000 | -78,290,000 | -100,337,000 | -126,153,000 | -141,284,000 | -150,679,000 | -147,226,000 | -210,953,000 | -163,081,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | -7.5% | 614 | 663 | 693 | 555 | 520 | 574 | 491 | 594 | 1,340 | 1,454 | 1,637 | 1,781 | 1,945 | 2,108 | 1,529 | 1,727 | 1,892 | 2,023 | 2,139 | 2,243 | 2,352 |
Current Assets | -14.2% | 247 | 288 | 351 | 199 | 160 | 167 | 255 | 337 | 832 | 904 | 1,098 | 1,216 | 1,293 | 1,613 | 967 | 1,152 | 1,220 | 1,301 | 1,365 | 1,419 | 1,725 |
Cash Equivalents | -4.4% | 165 | 173 | 239 | 113 | 66.00 | 81.00 | 106 | 207 | 402 | 353 | 440 | 374 | 324 | 1,199 | 347 | 382 | 300 | 281 | 222 | 417 | 952 |
Inventory | 53.7% | 21.00 | 14.00 | 4.00 | - | - | - | - | - | 1.00 | 14.00 | 18.00 | 11.00 | - | - | - | - | - | - | - | - | - |
Net PPE | -2.5% | 10.00 | 10.00 | 9.00 | 9.00 | 12.00 | 15.00 | 11.00 | 10.00 | 46.00 | 159 | 165 | 17.00 | 158 | 155 | 154 | 151 | 144 | 129 | 114 | 247 | 233 |
Goodwill | 0% | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 12.00 | 13.00 | 13.00 | 6.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 |
Liabilities | 4.5% | 391 | 374 | 338 | 359 | 361 | 393 | 228 | 220 | 469 | 470 | 437 | 426 | 422 | 426 | 409 | 442 | 421 | 387 | 367 | 358 | 351 |
Current Liabilities | 17.7% | 159 | 135 | 116 | 128 | 127 | 149 | 143 | 153 | 267 | 248 | 206 | 204 | 197 | 197 | 184 | 224 | 196 | 162 | 147 | 146 | 132 |
Shareholder's Equity | -23.0% | 223 | 289 | 355 | 196 | 159 | 180 | 263 | 374 | 871 | 985 | 1,200 | 1,355 | 1,523 | 1,682 | 1,120 | 1,285 | 1,472 | 1,636 | 1,772 | 1,885 | 2,001 |
Retained Earnings | -1.8% | -4,109 | -4,038 | -3,970 | -3,986 | -4,020 | -3,940 | -3,842 | -3,719 | -3,560 | -3,350 | -3,106 | -2,900 | -2,700 | -2,505 | -2,480 | -2,281 | -2,058 | -1,852 | -1,656 | -1,498 | -1,349 |
Additional Paid-In Capital | 0.1% | 4,334 | 4,328 | 4,322 | 4,186 | 4,181 | 4,126 | 4,109 | 4,096 | 4,441 | 4,338 | 4,311 | 4,260 | 4,227 | 4,190 | 3,607 | 3,568 | 3,533 | 3,489 | 3,430 | 3,387 | 3,355 |
Shares Outstanding | 0.5% | 107 | 106 | 106 | 83.00 | 82.00 | 74.00 | 74.00 | 71.00 | 68.00 | 67.00 | 67.00 | 62.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | 302 | - | - | - | 1,399 | - | - | - | 4,041 | - | - | - | 7,025 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | 15.0% | -61,846 | -72,763 | -86,600 | -56,320 | -77,026 | -94,358 | -125,296 | -139,725 | -146,939 | -145,648 | -203,327 | -155,193 | -148,780 | 39,743 | -206,121 | -158,976 | -113,381 | -137,873 | -154,154 | -129,731 | -74,473 |
Share Based Compensation | -15.4% | 4,868 | 5,754 | 5,391 | 4,679 | 9,211 | 8,908 | 12,390 | 26,086 | 28,142 | 31,160 | 42,527 | 32,991 | 38,818 | 48,529 | 36,293 | 34,631 | 38,546 | 55,111 | 32,341 | 29,987 | 29,798 |
Cashflow From Investing | 793.9% | 62,083 | 6,945 | 82,136 | 103,242 | 15,609 | 61,676 | 69,926 | 60,932 | 119,905 | 60,368 | 321,352 | 148,816 | -727,015 | 269,276 | 224,578 | 183,253 | 129,041 | 232,426 | -36,913 | -421,091 | 33,868 |
Cashflow From Financing | 90.6% | -42.00 | -445 | 130,456 | -115 | 46,325 | 8,034 | 9.00 | -174,014 | 75,868 | 396 | 3,796 | 1,432 | 1,198 | 543,122 | 963 | 2,005 | 4,178 | 4,781 | 10,223 | 1,921 | 658,793 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Revenue: | ||||
Total revenues | $ 12,392 | $ 71 | $ 21,663 | $ 3,534 |
Cost of product revenue | 10,955 | 0 | 23,895 | 10,056 |
Gross margin | 1,437 | 71 | (2,232) | (6,522) |
Operating expenses: | ||||
Selling, general and administrative | 40,703 | 33,402 | 118,406 | 106,201 |
Research and development | 45,463 | 53,149 | 133,881 | 194,864 |
Restructuring expenses | 0 | (1,699) | 0 | 4,940 |
Total operating expenses | 86,166 | 84,852 | 252,287 | 306,005 |
Gain from sale of priority review voucher, net | 0 | 0 | 92,930 | 0 |
Income (loss) from operations | (84,729) | (84,781) | (161,589) | (312,527) |
Interest income, net | 2,454 | 383 | 7,958 | 663 |
Other income (expense), net | 10,544 | 7,885 | 30,152 | 13,061 |
Income (loss) before income taxes | (71,731) | (76,513) | (123,479) | (298,803) |
Income tax (expense) benefit | 0 | (7) | 80 | (7) |
Net income (loss) | $ (71,731) | $ (76,520) | $ (123,399) | $ (298,810) |
Net income (loss) per share - basic (in dollars per share) | $ (0.66) | $ (0.94) | $ (1.15) | $ (3.91) |
Net income (loss) per share - diluted (in dollars per share) | $ (0.66) | $ (0.94) | $ (1.15) | $ (3.91) |
Weighted-average number of common shares used in computing net income (loss) per share - basic (in shares) | 109,098 | 81,543 | 106,924 | 76,361 |
Weighted-average number of common shares used in computing net income (loss) per share - diluted (in shares) | 109,098 | 81,543 | 106,924 | 76,361 |
Other comprehensive income (loss): | ||||
Total other comprehensive income (loss) | $ 137 | $ (214) | $ 1,843 | $ (1,719) |
Comprehensive income (loss) | (71,594) | (76,734) | (121,556) | (300,529) |
Product revenue, net | ||||
Revenue: | ||||
Revenue | 12,281 | 0 | 21,414 | 2,739 |
Other revenue | ||||
Revenue: | ||||
Revenue | $ 111 | $ 71 | $ 249 | $ 795 |
Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 165,347 | $ 113,006 |
Marketable securities | 8,946 | 67,321 |
Accounts receivable | 23,000 | 0 |
Prepaid expenses | 11,431 | 8,374 |
Inventory | 20,969 | 0 |
Other current assets | 17,383 | 10,787 |
Total current assets | 247,076 | 199,488 |
Marketable securities | 0 | 1,414 |
Property, plant and equipment, net | 9,972 | 9,362 |
Goodwill | 5,646 | 5,646 |
Intangible assets | 5,368 | 4,868 |
Operating lease right-of-use assets | 294,717 | 281,996 |
Restricted cash and other non-current assets | 50,829 | 52,128 |
Total assets | 613,608 | 554,902 |
Current liabilities: | ||
Accounts payable | 19,852 | 25,092 |
Deferred revenue | 9,653 | 1,502 |
Accrued expenses and other current liabilities | 57,768 | 50,483 |
Operating lease liability, current portion | 71,684 | 51,160 |
Total current liabilities | 158,957 | 128,237 |
Operating lease liability, net of current portion | 232,023 | 230,230 |
Other non-current liabilities | 92 | 92 |
Total liabilities | 391,072 | 358,559 |
Commitments and contingencies (Note 9) | ||
Stockholders’ equity: | ||
Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.01 par value, 250,000 shares authorized; 107,022 and 82,923 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 1,071 | 830 |
Additional paid-in capital | 4,333,594 | 4,186,086 |
Accumulated other comprehensive loss | (2,227) | (4,070) |
Accumulated deficit | (4,109,902) | (3,986,503) |
Total stockholders’ equity | 222,536 | 196,343 |
Total liabilities and stockholders’ equity | $ 613,608 | $ 554,902 |